new acute renal failure - columbia nephrologycolumbianephrology.org/lectures/arf.pdf · 2014. 9....

52
Acute Renal Failure An Update Jai Radhakrishnan, MD, MS, FASN, FACC Associate Professor of Clinical Medicine Columbia University

Upload: others

Post on 22-Oct-2020

1 views

Category:

Documents


0 download

TRANSCRIPT

  • Acute Renal FailureAn Update

    Jai Radhakrishnan, MD, MS, FASN, FACCAssociate Professor of Clinical Medicine

    Columbia University

  • Objectives

    Epidemiology of ARF

    Diagnostic workup

    Specific syndromes of ARF

    Treatment and Prevention

  • ARF-Definitions Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group Crit Care. 2004 Aug;8(4):R204

  • Changes in mortality in patients with acute renal failure over 47 years

    Ympa YP Am J Med. 2005 Aug;118(8):827-32.

  • Etiology of ARF

    Pre-renal (hemodynamic)

    Intra-Renal (parenchymal)

    Post-renal (obstructive)

  • ARF: Pre-renal

    Volume DepletionCardiacRedistributionHepatorenalsyndrome

    NSAIDSACE-inhibitors

    Prostaglandins Angiotensin-II

  • Hepatorenal Syndrome: Diagnostic Criteria

    Hepatology. 1996 Jan;23(1):164-76

    MAJOR CRITERIA: Chronic/Acute liver disease with advanced hepatic failure and portal hypertensionLow GFR (Creatinine>1.5mg/dL or CrCl

  • 100100

    9090

    8080

    7070

    6060

    5050

    4040

    3030

    2020

    1010

    00--1414 --1313 --1212 --1111 --1010 --99 --88 --77 --66 --55

    Agonist (Log M)Agonist (Log M)

    Edwards AJP 1989Edwards AJP 1989

    AVPAVPNENE

    100100

    9090

    8080

    7070

    6060

    5050

    4040

    3030

    2020

    1010

    00--1414 --1313 --1212 --1111 --1010 --99 --88 --77 --66 --55

    Agonist (Log M)Agonist (Log M)

    AVPAVPNENE

    % R

    educ

    tion

    in L

    umen

    Dia

    met

    er%

    Red

    uctio

    n in

    Lum

    en D

    iam

    eter

    Efferent and Afferent Arterioles of Rabbit

    Efferent Afferent

  • Terlipressin +/- Albumin In HRS

    Hepatology 36 (2002), pp. 941–948

  • Hepatorenal Syndrome Type I: Vasopressin in One Patient

    120120

    100100

    8080

    6060

    4040

    2020

    00

    120120

    100100

    8080

    6060

    4040

    2020

    00--66 --44 --22 00 22 44 66 88

    SBP SBP (mm Hg)(mm Hg)

    Time (hrs)Time (hrs)

    AVPAVP

    SPASPA

    SBP SBP (mm Hg)(mm Hg)

    UOUO(cc/h)(cc/h)

    UOUO(cc/h)(cc/h)

  • Diclofenac Residues as the Cause of Vulture population Decline in Pakistan

    Nature. 2004 Feb 12;427(6975):

  • ARF: Post-renal

    Consider obstruction in every patient with ARF.Sites of obstruction leading to ARF:

    Bladder neck obstructionBilateral ureters

    Urine volume variable.Renal USG or Bladder catheterization.

  • ARF: Intra-Renal

    VASCULARVascular occlusionAtheroembolicdiseaseThrombotic microangiopathy

    INTERSTITIALInterstitial nephritis

    GLOMERULARAcute/Rapidly progressive glomerulonephritis

    TUBULARCrystal ATN

  • Atheroembolic disease

    ARF precipitated by angiographyOften eosinophilia and low complementMulti-organ dysfunction, livedo reticularis, blue toesGenerally irreversible

  • Acute Interstitial Nephritis

    Triad of fever, skin rash and eosinophiliaEosinophiluriaDrugs: penicillin, cephalosporins, diuretics, NSAIDS, dilantinUsually completely reversible upon withdrawing drug?Glucocorticoids

  • Rapidly Progressive Glomerulonephritis

    ETIOLOGYImmune complex GN: -post infectious,SLE, IgAN, SBE, cryoglobulinemiaAnti GBM antibody diseaseVasculitis: -Wegener’s, microscopic PAN, idiopathic crescentic GN

    DIAGNOSTIC CLUESSystemic findingsSignificant proteinuria, RBC, RBC casts

  • Crystal-induced ARF

    Uric acid (tumor-lysis)Oxalate (ethylene glycol)MethotrexateAcyclovirSulfonamidesIndinavirPhospho Soda

    Uric Acid

    Oxalate

  • Indinavir- Urine Crystals

    Gagnon RF.. Am J Kidney Dis 2000 Sep;36(3):507-515

  • Osmotic Nephrosis

    SucroseMannitolIntravenous immunoglobulinRadiocontrast agents

    DextranHydroxyethyl starch

    Ebcioglu Z.. Kidney International (2006) 70, 1873–1876.

  • J Am Soc Nephrol. 2005 Nov;16(11):3389-96.

  • Etiology of ATN

    IschemicAll pre-renal causes

    Exogenous ToxinsAntibioticsContrastChemotherapyOrg. solvents, Heavy metals

    Endogenous Toxins

    HemoglobinMyoglobinLight chains

  • Radiocontrast NephropathyClinical Course:

    Onset of oliguria within 24 hoursPeak creatinine in 4-5 days followed by recovery in the majorityDifferential diagnosis: atheroembolic disease

    Risk factors: AgeChronic kidney disease esp. diabetesPre-renal azotemia (e.g. cirrhosis, CHF)Volume of contrast

  • Contrast Nephropathy RiskS Creatinine> 0.5 mg/dl or > 25%at 48-72 h

    Mehran R.. J Am Coll Cardiol. 2004 Oct 6;44(7):1393-9.

  • Heme Pigment Induced ATN

    Rhabdomyolysis: traumatic or non-traumaticIntravascular hemolysisMechanism uncertain: Vasoconstriction, precipitation/obstruction, toxicity of other breakdown productsConcomitant volume depletion

  • Aminoglycoside NephrotoxicityNon-oliguric renal failureOnset several days after treatmentRecovery is usually complete within 3 weeks

    Mingeot-Leclercq MP… Antimicrob Agents Chemother. 1999 May;43(5):1003-12.

  • Top 5 Causes of ARF

    Am J Kidney Dis. 2002 May;39(5):930-6

  • Urinary Indices in Oliguric ARF

    *UNa / PNa ÷ UCr / PCr

    Urinary Index Pre-renal ATN

    Osmolality (mOsom/kg)

    >500

  • Urine Microscopy

    Red Cell Cast WBC Cast

    Muddy (granular) Cast Broad Cast

  • Workup of Renal Failure

    Post-Renal

    Glomerular Vascular Interstitial Tubular

    Renal Pre-Renal

    Acute or Chronic

    RENAL FAILURE

    History, Physical, Urine analysis, USG

  • Treatment of ATN-2005

    SUPPORTIVE CARE• Acid-base/electrolyte balance• Fluid balance• Nutrition• Review of drugs• Dialysis:

    • PD, HD, Continuous modalities

  • Intensity of Renal Support in Critically Ill Patients with Acute Kidney Injury.

    N Engl J Med. 2008 May 20. [Epub ahead of print]

    35 ml/kg/h

    20 ml/kg/h

  • Course and Outcome of ATN

    Am J Kidney Dis. 2002 May;39(5):930-6

  • Bruce A. Molitoris & Robert Bacallao

    Pathogenesis of ATN

  • Tubuloglomerular feedback

    EndothelinAdenosine

    Nitric OxideProstacyclin

  • Source of ROS:XanthineDehydrogenaseNADH Oxidase

    Pathogenesis of ATN: Reactive Oxygen Species

  • QUESTION: What preventive strategies have been consistently shown to be effective against ATN?

    Maintaining euvolemia ?N-acetyl cysteine ?Dopamine ?Iso-osmolar contrast ?

  • Preventive StrategiesPOSITIVE:

    HydrationEQUIVOCAL:

    BicarbonateN-Acetyl CysteineTheophyllineIsoosmolar ContrastCRRT/Dialysis

    NEGATIVE:Atrial natriuretic peptide Anti-endothelinantagonistFenoldopam

  • The Data

    Effect on Mortality

    Effect on need for Renal Replacement Therapy

    Friedrich JO; Adhikari N; Herridge MS; Beyene J. Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death.Ann Intern Med 2005 Apr 5;142(7):510-24.

  • High-dose Furosemide for Established ARF

    338 pts with ARF on dialysisFurosemide (25mg/kg IV or 35mg/kg PO, or matched placebo) daily.No difference in :

    SurvivalRenal recovery

    Shorter time to 2L/day diuresis

    Am J Kidney Dis. 2004 Sep;44(3):402-9

  • Course and Outcome of ATN

    Am J Kidney Dis. 2002 May;39(5):930-6

  • ARF Outcomes after Discharge: Survival979 pts who received CRRT69% in-hospital mortalityPost discharge survival:

    6M: 89%5 Y: 50%

    Morgera, S. American Journal of Kidney Disease 2002; 40(2):275-279

  • Morgera, S. American Journal of Kidney Disease 2002; 40(2):275-279

    Korkeila, M. Nephrology, Dialysis, and Transplantation 2000

    77% assessed health as “Good to excellent”69% resumed working57% self-sustainingMost Common Complaints:

    Loss of energyDifficulty with heavy houseworkLimited physical mobility

    ARF: Outcomes after DischargeQuality of Life

  • Future Developments

    Biomarkers:Cell-based therapy

  • Current Status of Biomarkers

    Neutrophil Gelatinase-associated Lipocalcin(NGAL)Kidney Injury Molecule-1Interleukin 18

    Nickolas T.. Curr Opin Nephrol Hypertens. 2008 Mar;17(2):127-132

  • 1514131211109876543210

    25

    50

    75

    100

    125

    150

    175

    200

    225

    2 4 6 8 12 24 36 48 60 72 84 96 108 120

    Post CPB Time (hours)

    Urin

    e N

    GAL

    (ng/

    ml)

    No ARF(n=51)

    ARF(n=20)

    Serum Creat Rise

    Urine NGAL is upregulated 15-fold within 2 hours after CPB in patients who later develop ARF

    Lancet. 2005Apr;365(9466):1231-8.

  • 2100

    100

    200

    300

    400

    500

    600

    ARF(n=20)

    No ARF(n=51)

    Urin

    e N

    GAL

    (ng/

    ml)

    2 hr

    pos

    t CPB

    Urinary NGAL at 2 Hours Post CPB

    50

    The 2-hour urine NGAL was 50 ng/ml or higher in all patients who subsequently developed ARF

    Lancet. 2005Apr;365(9466):1231-8.

    Sensitivity: 100%Specificity: 98%PPV: 95%NPV: 100%

  • Ann Intern Med. 2008 Jun 3;148(11):810-9.

  • ConclusionsARF is common in hospitalized patients & has a high mortalityA significant number of patients recoverThe best (and least expensive) preventive strategy is to maintain euvolumia

    Acute Renal Failure�An UpdateObjectivesARF-Definitions �Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group Crit Care. 20Changes in mortality in patients with acute renal failure over 47 yearsEtiology of ARFARF: Pre-renal Hepatorenal Syndrome: �Diagnostic Criteria Terlipressin +/- Albumin In HRSDiclofenac Residues as the Cause of Vulture population Decline in PakistanARF: Post-renalARF: Intra-Renal Atheroembolic diseaseAcute Interstitial NephritisRapidly Progressive GlomerulonephritisCrystal-induced ARFIndinavir- Urine CrystalsOsmotic NephrosisEtiology of ATNRadiocontrast NephropathyContrast Nephropathy Risk�S Creatinine> 0.5 mg/dl or > 25%at 48-72 h Heme Pigment Induced ATNAminoglycoside NephrotoxicityTop 5 Causes of ARFUrinary Indices in Oliguric ARFUrine MicroscopyTreatment of ATN-2005Intensity of Renal Support in Critically Ill Patients with Acute Kidney Injury.�Course and Outcome of ATNTubuloglomerular feedbackPathogenesis of ATN: �Reactive Oxygen SpeciesQUESTION: What preventive strategies have been consistently shown to be effective against ATN?Preventive StrategiesThe DataHigh-dose Furosemide for Established ARFCourse and Outcome of ATNARF Outcomes after Discharge: SurvivalARF: Outcomes after Discharge� Quality of LifeFuture DevelopmentsCurrent Status of BiomarkersConclusions